Darin Kizer

474 total citations
7 papers, 237 citations indexed

About

Darin Kizer is a scholar working on Organic Chemistry, Molecular Biology and Toxicology. According to data from OpenAlex, Darin Kizer has authored 7 papers receiving a total of 237 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Organic Chemistry, 6 papers in Molecular Biology and 3 papers in Toxicology. Recurrent topics in Darin Kizer's work include Bioactive Compounds and Antitumor Agents (3 papers), Cancer therapeutics and mechanisms (3 papers) and Synthesis and Reactions of Organic Compounds (2 papers). Darin Kizer is often cited by papers focused on Bioactive Compounds and Antitumor Agents (3 papers), Cancer therapeutics and mechanisms (3 papers) and Synthesis and Reactions of Organic Compounds (2 papers). Darin Kizer collaborates with scholars based in United States and Japan. Darin Kizer's co-authors include Ronald E. Savage, Erika Volckova, Hui Wu, Xiu‐Sheng Miao, Rui‐Yang Yang, Mark A. Ashwell, Thomas Chan, Mark J. Kurth, Rebecca Miller and Syed Mashhood Ali and has published in prestigious journals such as Journal of Medicinal Chemistry, Tetrahedron Letters and Bioorganic & Medicinal Chemistry.

In The Last Decade

Darin Kizer

7 papers receiving 226 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Darin Kizer United States 7 161 135 57 23 19 7 237
Manal M. Kandeel Egypt 10 349 2.2× 94 0.7× 38 0.7× 43 1.9× 32 1.7× 30 395
Yoshiaki Washio United Kingdom 8 215 1.3× 192 1.4× 24 0.4× 30 1.3× 51 2.7× 11 373
Ola H. Rizk Egypt 10 312 1.9× 82 0.6× 26 0.5× 33 1.4× 20 1.1× 13 373
Cherng-Chyi Tzeng Taiwan 10 273 1.7× 185 1.4× 64 1.1× 42 1.8× 12 0.6× 16 401
Khehyong Ngu United States 9 262 1.6× 193 1.4× 36 0.6× 47 2.0× 9 0.5× 11 345
Enrico Perspicace France 13 297 1.8× 130 1.0× 28 0.5× 29 1.3× 14 0.7× 23 436
Kyung-Hwa Jeon South Korea 12 226 1.4× 212 1.6× 83 1.5× 51 2.2× 11 0.6× 13 393
Md. Ashraf India 9 353 2.2× 108 0.8× 27 0.5× 20 0.9× 11 0.6× 12 388
Amel M. Farrag Egypt 11 335 2.1× 143 1.1× 46 0.8× 47 2.0× 48 2.5× 23 414
Jaki R. Tamboli India 12 394 2.4× 198 1.5× 37 0.6× 38 1.7× 27 1.4× 16 494

Countries citing papers authored by Darin Kizer

Since Specialization
Citations

This map shows the geographic impact of Darin Kizer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darin Kizer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darin Kizer more than expected).

Fields of papers citing papers by Darin Kizer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darin Kizer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darin Kizer. The network helps show where Darin Kizer may publish in the future.

Co-authorship network of co-authors of Darin Kizer

This figure shows the co-authorship network connecting the top 25 collaborators of Darin Kizer. A scholar is included among the top collaborators of Darin Kizer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darin Kizer. Darin Kizer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Lapierre, Jean‐Marc, Sudharshan Eathiraj, Yanbin Liu, et al.. (2016). Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor. Journal of Medicinal Chemistry. 59(13). 6455–6469. 87 indexed citations
2.
Mavunkel, Babu, John Perumattam, Xuefei Tan, et al.. (2009). Piperidine-based heterocyclic oxalyl amides as potent p38α MAP kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 20(3). 1059–1062. 21 indexed citations
3.
Miao, Xiu‐Sheng, Ronald E. Savage, Caiyun Zhong, et al.. (2008). Identification of the in Vitro Metabolites of 3,4-Dihydro-2,2-dimethyl-2H-naphthol[1,2-b ]pyran-5,6-dione (ARQ 501; β-Lapachone) in Whole Blood. Drug Metabolism and Disposition. 36(4). 641–648. 25 indexed citations
4.
Miao, Xiu‐Sheng, Caiyun Zhong, Yunxia Wang, et al.. (2008). In vitro metabolism of β ‐lapachone (ARQ 501) in mammalian hepatocytes and cultured human cells. Rapid Communications in Mass Spectrometry. 23(1). 12–22. 19 indexed citations
5.
Yang, Rui‐Yang, Darin Kizer, Hui Wu, et al.. (2008). Synthetic methods for the preparation of ARQ 501 (β-Lapachone) human blood metabolites. Bioorganic & Medicinal Chemistry. 16(10). 5635–5643. 51 indexed citations
6.
McGarvey, Glenn J., et al.. (2003). Synthesis of α- and β-C-glycosides of N-acetylglucosamine. Tetrahedron Letters. 44(19). 3775–3779. 16 indexed citations
7.
Kizer, Darin, Rebecca Miller, & Mark J. Kurth. (1999). Fused pyrazolo heterocycles: intramolecular [3+2]-nitrile oxide cycloadditions applied to syntheses of pyrazolo [3,4-g] [2,1] dihydrobenzoisoxazol (in) es. Tetrahedron Letters. 40(18). 3535–3538. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026